Application of a genetic signature of late GU toxicity in SCIMITAR, a Post-op SBRT trial
Clinical and Translational Radiation Oncology (2023)
Predictors of genitourinary toxicity after post-prostatectomy radiotherapy remain elusive. A previously defined germline DNA signature (PROSTOX) has shown predictive ability for late grade ≥ 2 GU toxicity after intact prostate stereotactic body radiotherapy. We explore whether PROSTOX would predict toxicity among patients receiving post-prostatectomy SBRT on a phase II clinical trial.
Recommended citation: Kishan, A.U., Marco, N., Ma, T.M., Steinberg, M.L., Sachdeva, A., Cao, M., Ballas, L.K., Rietdorf, E., Telesca, D. and Weidhaas, J.B., 2023. Application of a genetic signature of late GU toxicity in SCIMITAR, a Post-op SBRT trial. Clinical and Translational Radiation Oncology, 39, p.100594.